Skip to main content

Table 1 Histomorphometric parameters of the sciatic nerve after treatment with bupivacaine hydrochloride (BHCl), liposome bupivacaine (LB) and saline in STZ-induced diabetic mice and nondiabetic control mice

From: Neurotoxicity of bupivacaine and liposome bupivacaine after sciatic nerve block in healthy and streptozotocin-induced diabetic mice

  

Treated nerves

Control nerves

Saline

BHCl

LB

Saline

BHCl

LB

Fibre density (mm− 2)

Diabetic

23724 (6888)

22862 (4349)

30259 (8511)

26232 (4743)

31717 (8258)

23347 (2872)

Nondiabetic

22492 (4881)

21582 (6144)††

21983 (3408)

25969 (2950)

29522 (3558)

25906 (5004)

Large fibre area per total area

Diabetic

65.20 (2.54)

62.63 (7.00)

64.03 (2.50)

67.93 (1.39)

64.58 (3.00)

67.64 (2.00)

Nondiabetic

66.91 (3.61)

63.95 (6.46)

65.71 (2.53)

65.87 (2.39)

65.19 (2.86)

67.72 (1.90)

Large fibre diameter (µm)

Diabetic

5.58 (0.65)

5.58

(0.54)

4.97 (0.72)

5.37 (0.48)

4.81 (0.68)

5.62 (0.29)

Nondiabetic

5.82 (0.69)

5.8

(0.75)††

5.68 (0.42)

5.27 (0.38)

4.94 (0.21)

5.42 (0.59)

Axon diameter (µm)

Diabetic

3.13 (0.41)

3.53

(0.31)# ††

2.79 (0.68)

2.97 (0.55)

2.85 (0.31)

3.36 (0.32)

Nondiabetic

3.26 (0.49)

3.55 (0.50)††

3.25 (0.17)

2.98 (0.09)

2.78 (0.16)

3.04 (0.27)

Myelin width (µm)

Diabetic

1.23 (0.18)

1.01 (0.17)*

1.09 (0.06)

1.14 (0.12)

1.06 (0.19)

1.14 (0.09)

Nondiabetic

1.28 (0.19)

1.12 (0.29)*

1.21 (0.22)

1.15 (0.20)

1.08 (0.07)

1.19 (0.20)

G-ratio (axon diameter/large fibre diameter)

Diabetic

0.56 (0.03)

0.63 (0.04)** ##

0.56 (0.06)

0.55 (0.06)

0.60 (0.09)

0.60 (0.04)

Nondiabetic

0.56 (0.04)

0.62

(0.06)** ##

0.58 (0.05)

0.57 (0.04)

0.56 (0.02)

0.56 (0.03)

  1. Values are means (SD), n = 6 for each study group. From two-way ANOVA: *P < 0.05, **P < 0.01 for BHCl- versus saline-treated nerves, and #P < 0.05, ##P < 0.01 for BHCl- versus LB-treated nerves. From dependent t test: †P < 0.05, †† P < 0.01 between treated and control nerves